Authors
Latest:
Risky BusinessEvery quarter, pharmaceutical manufacturers confront a dizzying array of price reporting obligations. Participation in the Medicare, Medicaid, Veterans Administration (VA), and Public Health Service (PHS) programs requires manufacturers to collect, organize, distill and manipulate vast quantities of information, and to generate from that data reportable figures that can have an enormous impact on the company's bottom line. It is critical that these figures be correct, not only to help ensure the integrity of these public programs, but because submission of false data to a federal agency is a prosecutable criminal offense, and the civil penalties and exposure can be staggering.
Latest:
Sales SlipOne fortunate consequence of a slower job market is that tenure levels are increasing: 80 percent of sales managers now have at least two years experience under their belt.
Latest:
Sales and Marketing: Where the Buck StopsCost-shifting is still one of the favorite tools in almost all employers' cost-cutting toolboxes. But many fear that shifting too many costs to workers will backfire. Low co-pays keep people healthy and on the job: a big return on investment.
Latest:
What Pharma Wants From IT TodayPilot projects involving RFID technology are appearing at some major pharma companies. But uptake of RFID-based solutions remains limited due to concerns about accuracy, reliability, and ROI.
Latest:
Informatics RulesWithout common reporting standards in place, researchers have little incentive to share data with scientists elsewhere in the company. When researchers don't sharedata on a regular basis, they can begin to feel proprietary about their work-and even less inclined to disclose their results.
Latest:
Drug Shortages: Not Going Away Anytime SoonAlbert Wertheimer, PhD, MBA, Professor of Pharmaceutical Economics at Temple University and a member of Pharm Exec's Editorial Advisory Board, shows how the simple matter of a drug shortage is not a simple matter at all.
Latest:
Extending the Product LifelinePharma companies seem to have forgotten one key lesson: Blockbusters are made, not discovered. Few drugs achieve top sales based on their initial formulation and indications.
Latest:
The New Era of Risk ManagementFDA has issued the industry a new charge-pay closer attention to risk management. Now that prescription drug user fees have helped the agency approve candidates more rapidly, FDA has returned to its basic mandate: assuring that marketed pharmaceuticals are safe. In the past, that meant clear labeling with adequate directions and warnings based on clinical trials. The agency now believes that product safety extends beyond warning labels and wants to ensure that prescriptions are used safely as well. As a result, it is asking the pharma industry to demonstrate products' safety before approval and to further control their use after
Latest:
Post-Genomic Drug Development. Is Pharma Ready?Hard on the heels of the June 2000 announcement that the human genome sequence was completed came a wide array of articles on genomics' impact on drug discovery and development
Latest:
Blueprint for a Great LeaderIs there a formula for the perfect biotech or pharmaceutical executive? As a candidate to be the next CEO of Pfizer or Amgen, it is better to have a PhD in microbiology or an MBA combined with a medical degree? Does a lifetime in the lab beat out a decade of sales and marketing experience?
Latest:
Pricing PressuresDuring the 2000 US election, prescription costs-especially for seniors-was a hot issue that both parties offered to resolve. Intervening events have since distracted the federal government from domestic healthcare issues, leaving states to take the initiative in lowering drug expenditures. Two states' programs led the way, drawing legal challenges from the pharmaceutical industry. Recent opinions by US courts of appeals in those cases reached conflicting results; but viewed together, they provide guidance for the types of state plans that will be sustained. Meanwhile, other programs are making their way through state legislatures around the country.
Latest:
Your new competition...It's not who you think it isDemands on physicians aren't just coming from reps.
Latest:
In Establishing the Evidence Base, He Made Science CountRobert Seidman, Former Chief Pharmacy Officer, Wellpoint
Latest:
It's All in the DetailsBrand managers assume that more information leads to more effectiveness. Unfortunately, the reverse is true.
Latest:
New Gains for PainThe global pain market will reach nearly $29.8 billion in 2008, of which $21.8 billion will come from the United States.
Latest:
The Rise and Fall of Pharma ReputationsAs a reputation driver, ethical behavior has increased steadily in importance over the last three years.
Latest:
Direct to Consumer: HIV and AdherenceThe flaw lies not in the lack of patient information, but rather in the way they process it.
Latest:
BioTech's New Business ModelCoined in the early 1940s, the hybrid term "biotech" has sustained its save-the-world aura and futurist allure. During the industry's nascent years, Amgen, Genentech, and other barrier-breaking companies were mere fledgling operations with products still in the pure science phase and their only "revenue" the hope of curing some of the world's ills.
Latest:
Also Known As...The Value of Generic NamesIn the world of pharmaceutical names, the trademark has always been the star, and every other word has played a supporting role. But recent developments at FDA-and the industry's response to those developments-have set the stage for a new approach to nomenclature.
Latest:
Key Opinion Leaders Interactions with PharmaData suggest that pharma companies engage the same key opinion leaders on assignments in three to seven departments or product groups at once.
Latest:
Pfizer Can Mold Its Future by Learning from the PastPfizer Chairman and CEO Hank McKinnell sees the company's $58 billion blockbuster acquisition of Pharmacia as the key to Pfizer's leadership in pharmaceutical markets around the globe.
Latest:
Beyond TrainingHow to Hire the Right Reps, Train Them to Excel, and Retain Them for the Long Run
Latest:
It's All in the DetailsBrand managers assume that more information leads to more effectiveness. Unfortunately, the reverse is true.
Latest:
Predicting Success: A Pipeline ReportMuch has been said about pharma's R&D lag, but a closer look at the candidates currently in Phase III shows that what the pipeline lacks in quantity it makes up for in quality. This Pharmaceutical Executive pipeline report identifies some of the top candidates in five categories: women's health, oncology, central nervous system (CNS), cardiovascular disease (CVD), and metabolic/ endocrine diseases.
